Mr. Murray brings more than 25 years of experience leading commercial strategy, global product launches, and customer-facing organizations in biotechnology and pharmaceutical companies.
He joins Vor Bio from Sarepta Therapeutics, where he most recently served as Executive Vice President, Chief Customer Officer. In that role, he led the commercial and medical affairs organizations, along with the international business unit. Under his leadership, Sarepta achieved approximately $1.8 billion in net product revenue in 2024. While at Sarepta he oversaw multiple product launches, including the launch of the first RNA therapy and first gene therapy for duchenne muscular dystrophy.
Over the course of his career, Mr. Murray has led or supported more than a dozen product launches, including INCIVEK at Vertex Pharmaceutics, Inc., the fastest launch to $1 billion in biotech history at the time, and multiple global rollouts at Gilead Sciences, Inc., Biogen Inc., and Johnson & Johnson.
Mr. Murray holds an MBA from Queen’s University in Ontario, Canada, and a Bachelor of Commerce from the University of Alberta.